TapewireFind a company

organization · Reporting owner

Omega Fund IV, L.P.

Disclosed activity across 3 companies

Tapewire entity
129051
SEC CIK
0001528382

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kezar Life Sciences, Inc.

Report date June 25, 2018 · Filed June 25, 2018

Jointly reported with Omega Fund IV GP, L.P., Omega Fund IV G.P. Manager, Ltd., Stampacchia Otello, Lim Richard J., Paster Anne-Mari

Section 16 reporting ended · disclosed 2018-06-25. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect315,489 Reported balance After 2018-06-25 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-06-25 · Conversion · Acquired 315,489 · Balance 315,489

F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

Common StockSEC Table I · non-derivativeDirect693,272 Reported balance After 2018-06-25 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2018-06-25 · Conversion · Acquired 377,783 · Balance 693,272

F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

Common StockSEC Table I · non-derivativeIndirectBy Omega IV693,272 Last balance in matching sequence After 2018-06-25 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 2 · 2018-06-25 · Conversion · Acquired 315,489 · Balance 315,489

F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

Row 4 · 2018-06-25 · Conversion · Acquired 377,783 · Balance 693,272

F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-06-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2018-06-25 · Conversion · Disposed 315,489 · Balance 0

F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectBy Omega IV0 Reported balance After 2018-06-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2018-06-25 · Conversion · Disposed 315,489 · Balance 0

F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-06-25 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2018-06-25 · Conversion · Disposed 377,783 · Balance 0

F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectBy Omega IV0 Reported balance After 2018-06-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2018-06-25 · Conversion · Disposed 377,783 · Balance 0

F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

Replimune Group, Inc.

Report date March 14, 2022 · Filed March 17, 2022

Jointly reported with Omega Fund IV GP, L.P., Omega Fund IV G.P. Manager, Ltd., Stampacchia Otello

Section 16 reporting ended · disclosed 2022-03-17. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Otello Stampacchia4,763,380 Last balance in matching sequence After 2022-03-14 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2022-03-14 · Exercise / conversion · Acquired 16,500 · Balance 4,779,880

F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager.

Row 2 · 2022-03-14 · Sale · Disposed 16,500 · Balance 4,763,380

F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager.

Common StockSEC Table I · non-derivativeDirect4,673,380 Last balance in matching sequence After 2022-03-16 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 3 · 2022-03-15 · Sale · Disposed 45,000 · Balance 4,718,380

F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.

Row 4 · 2022-03-16 · Sale · Disposed 6,238 · Balance 4,712,142

F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.

Row 5 · 2022-03-16 · Sale · Disposed 38,762 · Balance 4,673,380

F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.

Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.78 · Expires 2030-04-01IndirectBy Otello Stampacchia16,500 Reported balance After 2022-03-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2022-03-14 · Exercise / conversion · Disposed 16,500 · Balance 16,500

F3: Stock options vested 100% on April 1, 2021.

F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.

F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager.

F3: Stock options vested 100% on April 1, 2021.

Section 16 reporting ended · disclosed 2018-07-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect979,179 Reported balance After 2018-07-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-07-02 · Conversion · Acquired 979,179 · Balance 979,179

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Common StockSEC Table I · non-derivativeDirect1,458,424 Reported balance After 2018-07-02 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2018-07-02 · Conversion · Acquired 1,458,424 · Balance 1,458,424

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Common StockSEC Table I · non-derivativeIndirectBy Omega IV979,179 Reported balance After 2018-07-02 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2018-07-02 · Conversion · Acquired 979,179 · Balance 979,179

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy Omega V1,458,424 Reported balance After 2018-07-02 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2018-07-02 · Conversion · Acquired 1,458,424 · Balance 1,458,424

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2018-07-02 · Conversion · Disposed 2,500,000 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-07-02 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2018-07-02 · Conversion · Disposed 5,800,000 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy Omega IV0 Reported balance After 2018-07-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2018-07-02 · Conversion · Disposed 2,500,000 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-07-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2018-07-02 · Conversion · Disposed 1,676,348 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-07-02 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2018-07-02 · Conversion · Disposed 2,000,103 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Omega IV0 Reported balance After 2018-07-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2018-07-02 · Conversion · Disposed 1,676,348 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-07-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2018-07-02 · Conversion · Disposed 1,263,484 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-07-02 transaction · row 15 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 15 · 2018-07-02 · Conversion · Disposed 302,173 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectBy Omega IV0 Reported balance After 2018-07-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2018-07-02 · Conversion · Disposed 1,263,484 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy Omega V0 Reported balance After 2018-07-02 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2018-07-02 · Conversion · Disposed 5,800,000 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Omega V0 Reported balance After 2018-07-02 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2018-07-02 · Conversion · Disposed 2,000,103 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectBy Omega V0 Reported balance After 2018-07-02 transaction · row 16 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 16 · 2018-07-02 · Conversion · Disposed 302,173 · Balance 0

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionSeries A Preferred Stock · Derivative 5,800,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 12

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega V

Disclosed balance after: 0

Underlying: Common Stock · 1,044,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F3 · ownership.direct: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionSeries A Preferred Stock · Derivative 5,800,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 11

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,044,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionSeries C Preferred Stock · Derivative 1,263,484 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 10

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega IV

Disclosed balance after: 0

Underlying: Common Stock · 227,429 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionSeries C Preferred Stock · Derivative 1,263,484 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 9

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 227,429 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionSeries B Preferred Stock · Derivative 1,676,348 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 8

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega IV

Disclosed balance after: 0

Underlying: Common Stock · 301,745 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionSeries B Preferred Stock · Derivative 1,676,348 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 7

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 301,745 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionSeries A Preferred Stock · Derivative 2,500,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 6

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega IV

Disclosed balance after: 0

Underlying: Common Stock · 450,004 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionSeries A Preferred Stock · Derivative 2,500,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 5

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 450,004 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionCommon Stock 1,458,424 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · nonDerivative · entry 4

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega V

Disclosed balance after: 1,458,424

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F3 · ownership.direct: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionCommon Stock 1,458,424 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · nonDerivative · entry 3

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,458,424

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionCommon Stock 979,179 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · nonDerivative · entry 2

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega IV

Disclosed balance after: 979,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 18:44 UTC Translate Bio, Inc. TBIO · Entity 135439 ConversionCommon Stock 979,179 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-019324 · doc4.xml · nonDerivative · entry 1

Omega Fund IV, L.P. · CIK 0001528382 · 10% owner

Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner

Omega Fund V, L.P. · CIK 0001641354 · 10% owner

Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner

Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner

Stampacchia Otello · CIK 0001361712 · 10% owner

Lim Richard J. · CIK 0001623720 · 10% owner

Paster Anne-Mari · CIK 0001652863 · 10% owner

Nessi Claudio · CIK 0001722050 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 979,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 25, 2018 19:07 UTC Kezar Life Sciences, Inc. KZR · Entity 12111 ConversionSeries B Redeemable Convertible Preferred Stock · Derivative 377,783 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-017995 · doc4.xml · derivative · entry 8

Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner

Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner

Stampacchia Otello · CIK 0001361712 · Former 10% Owner

Lim Richard J. · CIK 0001623720 · Former 10% Owner

Paster Anne-Mari · CIK 0001652863 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega IV

Disclosed balance after: 0

Underlying: Common Stock · 377,783 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

F3 · derivative.exercise_date: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

F3 · derivative.expiration_date: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

Read SEC document
June 25, 2018 Filed Jun 25, 2018 19:07 UTC Kezar Life Sciences, Inc. KZR · Entity 12111 ConversionSeries B Redeemable Convertible Preferred Stock · Derivative 377,783 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-017995 · doc4.xml · derivative · entry 7

Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner

Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner

Stampacchia Otello · CIK 0001361712 · Former 10% Owner

Lim Richard J. · CIK 0001623720 · Former 10% Owner

Paster Anne-Mari · CIK 0001652863 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 377,783 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

F3 · derivative.exercise_date: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

F3 · derivative.expiration_date: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 25, 2018 19:07 UTC Kezar Life Sciences, Inc. KZR · Entity 12111 ConversionSeries A Redeemable Convertible Preferred Stock · Derivative 315,489 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-017995 · doc4.xml · derivative · entry 6

Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner

Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner

Stampacchia Otello · CIK 0001361712 · Former 10% Owner

Lim Richard J. · CIK 0001623720 · Former 10% Owner

Paster Anne-Mari · CIK 0001652863 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega IV

Disclosed balance after: 0

Underlying: Common Stock · 315,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F1 · derivative.exercise_date: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F1 · derivative.expiration_date: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

Read SEC document
June 25, 2018 Filed Jun 25, 2018 19:07 UTC Kezar Life Sciences, Inc. KZR · Entity 12111 ConversionSeries A Redeemable Convertible Preferred Stock · Derivative 315,489 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-017995 · doc4.xml · derivative · entry 5

Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner

Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner

Stampacchia Otello · CIK 0001361712 · Former 10% Owner

Lim Richard J. · CIK 0001623720 · Former 10% Owner

Paster Anne-Mari · CIK 0001652863 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 315,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F1 · derivative.exercise_date: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F1 · derivative.expiration_date: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 25, 2018 19:07 UTC Kezar Life Sciences, Inc. KZR · Entity 12111 ConversionCommon Stock 377,783 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-017995 · doc4.xml · nonDerivative · entry 4

Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner

Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner

Stampacchia Otello · CIK 0001361712 · Former 10% Owner

Lim Richard J. · CIK 0001623720 · Former 10% Owner

Paster Anne-Mari · CIK 0001652863 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega IV

Disclosed balance after: 693,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

Read SEC document
June 25, 2018 Filed Jun 25, 2018 19:07 UTC Kezar Life Sciences, Inc. KZR · Entity 12111 ConversionCommon Stock 377,783 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-017995 · doc4.xml · nonDerivative · entry 3

Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner

Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner

Stampacchia Otello · CIK 0001361712 · Former 10% Owner

Lim Richard J. · CIK 0001623720 · Former 10% Owner

Paster Anne-Mari · CIK 0001652863 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 693,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 25, 2018 19:07 UTC Kezar Life Sciences, Inc. KZR · Entity 12111 ConversionCommon Stock 315,489 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-017995 · doc4.xml · nonDerivative · entry 2

Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner

Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner

Stampacchia Otello · CIK 0001361712 · Former 10% Owner

Lim Richard J. · CIK 0001623720 · Former 10% Owner

Paster Anne-Mari · CIK 0001652863 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Omega IV

Disclosed balance after: 315,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

Read SEC document
June 25, 2018 Filed Jun 25, 2018 19:07 UTC Kezar Life Sciences, Inc. KZR · Entity 12111 ConversionCommon Stock 315,489 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-017995 · doc4.xml · nonDerivative · entry 1

Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner

Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner

Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner

Stampacchia Otello · CIK 0001361712 · Former 10% Owner

Lim Richard J. · CIK 0001623720 · Former 10% Owner

Paster Anne-Mari · CIK 0001652863 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 315,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.